AbbVie Inc

Drug Manufacturers-General

Prices are adjusted according to historical splits.

AbbVie Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$266.26 billion
Book Value:
Revenue TTM:
$58.05 billion
Operating Margin TTM:
Gross Profit TTM:
$41.53 billion
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

AbbVie Inc had its IPO on 2013-01-02 under the ticker symbol ABBV.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. AbbVie Inc has a staff strength of 50,000 employees.

Stock update

Shares of AbbVie Inc opened at $149.5 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $147.62 - $149.6, and closed at $149.27.

This is a +0.15% increase from the previous day's closing price.

A total volume of 1,853,169 shares were traded at the close of the day’s session.

In the last one week, shares of AbbVie Inc have increased by +0.72%.

AbbVie Inc's Key Ratios

AbbVie Inc has a market cap of $266.26 billion, indicating a price to book ratio of 18.2288 and a price to sales ratio of 4.9887.

In the last 12-months AbbVie Inc’s revenue was $58.05 billion with a gross profit of $41.53 billion and an EBITDA of $31.09 billion. The EBITDA ratio measures AbbVie Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, AbbVie Inc’s operating margin was 38.97% while its return on assets stood at 9.91% with a return of equity of 72.39%.

In Q4, AbbVie Inc’s quarterly earnings growth was a negative -38.8% while revenue growth was a positive 1.6%.

AbbVie Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $6.63 per share while it has a forward price to earnings multiple of 14.3885 and a PEG multiple of 1.2788. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AbbVie Inc’s profitability.

AbbVie Inc stock is trading at a EV to sales ratio of 6.0409 and a EV to EBITDA ratio of 13.7968. Its price to sales ratio in the trailing 12-months stood at 4.9887.

AbbVie Inc stock pays annual dividends of $5.71 per share, indicating a yield of 3.81% and a payout ratio of 41.41%.

Balance sheet and cash flow metrics

Total Assets
$138.81 billion
Total Liabilities
$29.54 billion
Operating Cash Flow
Capital Expenditure
$213 million
Dividend Payout Ratio

AbbVie Inc ended 2024 with $138.81 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $138.81 billion while shareholder equity stood at $17.25 billion.

AbbVie Inc ended 2024 with $2.19 billion in deferred long-term liabilities, $29.54 billion in other current liabilities, 18000000.00 in common stock, $4.78 billion in retained earnings and $32.16 billion in goodwill. Its cash balance stood at $9.20 billion and cash and short-term investments were $9.23 billion. The company’s total short-term debt was $4,136,000,000 while long-term debt stood at $59.14 billion.

AbbVie Inc’s total current assets stands at $28.46 billion while long-term investments were $241.00 million and short-term investments were $28.00 million. Its net receivables were $11.25 billion compared to accounts payable of $25.40 billion and inventory worth $3.58 billion.

In 2024, AbbVie Inc's operating cash flow was $-448000000.00 while its capital expenditure stood at $213 million.

Comparatively, AbbVie Inc paid $0.41 in dividends in 2024.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

AbbVie Inc stock is currently trading at $149.27 per share. It touched a 52-week high of $169.4595 and a 52-week low of $169.4595. Analysts tracking the stock have a 12-month average target price of $163.22.

Its 50-day moving average was $145.02 and 200-day moving average was $148.06 The short ratio stood at 1.87 indicating a short percent outstanding of 0%.

Around 11.8% of the company’s stock are held by insiders while 7152.7% are held by institutions.

Frequently Asked Questions About AbbVie Inc

The stock symbol (also called stock or share ticker) of AbbVie Inc is ABBV

The IPO of AbbVie Inc took place on 2013-01-02

Similar Industry Stocks (Drug Manufacturers-General)

Last Price
India Glycols Limited (INDIAGLYCO)
Nitches Inc (NICH)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet’s diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson’s disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.


1 North Waukegan Road, North Chicago, IL, United States, 60064-6400